Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes

International Journal of Antimicrobial Agents

Volumn 34, Issue 6, 2009, Pages 550-554

  Arhin, Francis F ^a   McKay, Geoffrey A ^a   Beaulieu, Sylvain ^a   Sarmiento, Ingrid ^a   Parr Jr , Thomas R ^a   Moeck, Gregory ^a  

^a The Medicines Company   (Canada)

Author keywords

Bactericidal; Lipoglycopeptide; Resistance

Indexed keywords

DAPTOMYCIN; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; LINEZOLID; ORITAVANCIN; PENICILLIN G; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; SKIN STRUCTURE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; GLYCOPEPTIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TIME FACTORS;

EID: 70350410262     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.08.012     Document Type: Article

References (25)

1. Dinkla K., Rohde M., Jansen W.T., Kaplan E.L., Chhatwal G.S., and Talay S.R. Rheumatic fever-associated Streptococcus pyogenes isolates aggregate collagen. J Clin Invest 111 (2003) 1905-1912
2. Gracia M., Díaz C., Coronel P., Gimeno M., García-Rodas R., Rodríguez-Cerrato V., et al. Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program. Diagn Microbiol Infect Dis 64 (2009) 52-56
3. Michos A.G., Bakoula C.G., Braoudaki M., Koutouzi F.I., Roma E.S., Pangalis A., et al. Macrolide resistance in Streptococcus pyogenes: prevalence, resistance determinants and emm types. Diagn Microbiol Infect Dis 64 (2009) 295-299
4. Schwalbe R.S., McIntosh A.C., Qaiyumi S., Johnson J.A., Johnson R.J., Furness K.M., et al. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother 40 (1996) 2416-2419
5. McKay G.A., Beaulieu S., Arhin F.F., Belley A., Sarmiento I., Parr Jr. T.R., et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 63 (2009) 1191-1199
6. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Wayne, PA: NCCLS; 1999.
7. US Food and Drug Administration. Division of Antiinfective and Ophthalmology Drug Products (HFD-520)-Microbiological data for antibacterial drug products-development, analysis, and presentation. FDA; 2005.
8. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering Jr. R.C., and Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42 (2004) 2398-2402
9. Pankey G.A., and Sabath L.D. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 38 (2004) 864-870
10. Daum R.S. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 357 (2007) 380-390
11. Moise P.A., Sakoulas G., Forrest A., and Schentag J.J. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51 (2007) 2582-2586
12. Finberg R.W., Moellering Jr. R.C., Tally F.P., Craig W.A., Pankey G.A., Dellinger E.P., et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 39 (2004) 1314-1320
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
14. Arhin F.F., Sarmiento I., Belley A., McKay G.A., Draghi D.C., Grover P., et al. Effect of polysorbate-80 on oritavancin binding to plastic surfaces-implications for susceptibility testing. Antimicrob Agents Chemother 52 (2008) 1597-1603
15. Brickner S.J., Hutchinson D.K., Barbachyn M.R., Manninen P.R., Ulanowicz D.A., Garmon S.A., et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J Med Chem 39 (1996) 673-679
16. Van Bambeke F., Van Laethem Y., Courvalin P., and Tulkens P.M. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 64 (2004) 913-936
17. Amsden G.W. Tables of antimicrobial agent pharmacology. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases. 6th ed. (2005), Elsevier Churchill Livingstone, Philadelphia, PA
18. Chambers H. Penicillins. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases. 6th ed. (2005), Elsevier Churchill Livingstone, Philadelphia, PA
19. 14C]oritavancin in human plasma at 1, 10 and 91 μg/mL employing a dextran coated charcoal adsorption method. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16-19 December 2001; Chicago, IL. Washington, DC: ASM Press; 2001 [Abstract A-2193].
20. Swartz M.N., and Pasternack M.S. Cellulitis and subcutaneous tissue infections. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases. 6th ed. (2005), Elsevier Churchill Livingstone, Philadelphia, PA
21. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M7-A8. Wayne, PA: CLSI; 2009.
22. Nielsen E.I., Viberg A., Löwdin E., Cars O., Karlsson M.O., and Sandström M. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother 51 (2007) 128-136
23. Goldstein B.P., Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 51 (2007) 1150-1154
24. Krause K.M., Renelli M., Difuntorum S., Wu T.X., Debabov D.V., and Benton B.M. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob Agents Chemother 52 (2008) 2647-2652
25. Rubino C.M., Van Wart S.A., Bhavnani S.M., Ambrose P.G., McCollam J.M., and Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 53 (2009) 4422-4428